Abstract
The present study was carried out to evaluate whether measured-creatinine clearance (measured-CrCl) and Cockcroft and Gault-CrCl (CG-CrCl) are capable of appropriately detecting a decline in renal function in lung cancer patients, including elderly patients, and to clarify a CrCl level with which to discriminate between patients with or without renal impairment. The measured-CrCl prior and subsequent to platinum-based chemotherapy of lung cancer patients was retrospectively analyzed. Measured-CrCl and CG-CrCl were evaluated prior and subsequent to platinum-based chemotherapy for lung cancer. Measured-CrCl and CG-CrCl in 59 lung cancer patients including 25 patients aged ≥65 years were retrospectively analyzed. In patients treated with carboplatin-based chemotherapy, measured-CrCl was indicative of a decline in renal function, whereas CG-CrCl was not. The optimal measured-CrCl level was <60 ml/min post-pretreatment and >90 ml/min at pre-treatment. In cases with pre-treatment measured-CrCl levels of >90 ml/min, favorable renal function is necessary in order to carry out platinum-based chemotherapy in lung cancer patients, including the elderly.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
